It is made available under a CC-BY 4.0 International license .

1

1	Ignoring transmission dynamics leads to underestimation of the impact of a novel
2	intervention against mosquito-borne disease
3	Sean M. Cavany*, John H. Huber*, Annaliese Wieler, Quan Minh Tran, Manar Alkuzweny,
4	Margaret Elliott, Guido España, Sean M. Moore, T. Alex Perkins
5	Department of Biological Sciences and Eck Institute for Global Health, University of Notre Dame
6	*Contributed Equally
7	For correspondence: Sean Cavany (<u>scavany@kolabnow.com</u>), John Huber (jhuber3@nd.edu),
8	and Alex Perkins (<u>taperkins@nd.edu</u>).
9	Key words: Mathematical modeling, vector control, dengue, Wolbachia, cluster-randomized
10	trials, bias
11	Abstract
12	New vector-control technologies to fight mosquito-borne diseases are urgently needed, the
13	adoption of which depends on efficacy estimates from large-scale cluster-randomized trials
14	(CRTs). The release of Wolbachia-infected mosquitoes is one promising strategy to curb
15	dengue virus (DENV) transmission, and a recent CRT reported impressive reductions in dengue
16	incidence following the release of these mosquitoes. Such trials can be affected by multiple
17	sources of bias, however. We used mathematical models of DENV transmission during a CRT
18	of Wolbachia-infected mosquitoes to explore three such biases: human movement, mosquito
19	movement, and coupled transmission dynamics between trial arms. We show that failure to
20	account for each of these biases would lead to underestimated efficacy, and that the majority of
21	this underestimation is due to a heretofore unrecognized bias caused by transmission coupling.
22	Taken together, our findings suggest that Wolbachia-infected mosquitoes could be even more
23	promising than the recent CRT suggested. By emphasizing the importance of accounting for
24	transmission coupling between arms, which requires a mathematical model, our results highlight
25	the key role that models can play in interpreting and extrapolating the results from trials of
26	vector control interventions.

It is made available under a CC-BY 4.0 International license .

3

27 Competing interests

28 The authors declare no competing interest.

29 Funding

- 30 This work was funded by the NIH National Institute of General Medical Sciences R35 MIRA
- 31 program (R35GM143029). John Huber was additionally supported by an NSF Graduate
- 32 Research Fellowship.

33 Data availability

- 34 All code and other files to reproduce our results is available at:
- 35 <u>https://github.com/scavany/awed_trial_modeling/</u>
- 36

37 Introduction

38 Dengue virus (DENV) poses a risk to around half the world's population due to the widespread 39 abundance of its Aedes mosquito vectors [1]. Historically, the success of dengue control has 40 been limited by challenges such as the expanding distribution of Aedes aegypti due to 41 urbanization and land-use changes, and ineffective or sub-optimally applied control strategies 42 [2,3]. One novel control strategy that holds promise is the release of mosquitoes infected with 43 Wolbachia, a vertically transmitted intracellular bacteria that reduces the ability of Aedes aegypti 44 mosquitoes to transmit DENV [4]. A cluster-randomized, controlled trial conducted between 45 2018 and 2020 in Yogyakarta, Indonesia (Applying Wolbachia to Eliminate Dengue, AWED) 46 [5,6] estimated that release of *Wolbachia*-infected mosquitoes had a protective efficacy against 47 symptomatic, virologically confirmed dengue of 77.1% (95% confidence interval: 65.3-84.9%) 48 [7].

There are at least three factors that can result in underestimated efficacy in this type of trial. All operate by making outcomes in treatment and control clusters appear more similar than if these factors were not at play, although they result in this for different reasons. First, the movement of humans between control and treated clusters can increase the exposure to DENV

It is made available under a CC-BY 4.0 International license .

5

53 of study subjects residing in treatment clusters and lower the exposure of subjects residing in 54 control clusters [8]. Second, the movement of mosquitoes between arms can lead to an 55 appreciable proportion of mosquitoes in control clusters infected with Wolbachia, lowering these 56 mosquitoes' ability to transmit DENV and introducing a source of contamination across trial 57 arms. Third, the dynamic, spatially localized nature of DENV transmission [9,10] implies that 58 suppression of transmission in treated clusters could influence transmission in neighboring 59 control clusters, thereby reducing incidence in both trial arms. Hereafter, we refer to each of 60 these three forms of bias as "human movement," "mosquito movement," and "transmission 61 coupling," respectively.

In their per-protocol analyses, Utarini *et al.* [7] acknowledged the potential effects of human and mosquito movement in their per-protocol analysis, and by incorporating recent travel and *Wolbachia* prevalence into their efficacy calculations did not detect a difference in efficacy from that estimated in the intention-to-treat analysis. Nevertheless, the analysis of the AWED trial by Utarini *et al.* [7] did not account for transmission coupling, and they noted that follow-up analyses were needed to further explore the potential for bias due to human and mosquito movement.

69 Understanding the magnitude of such biases is important when seeking to extrapolate 70 the impact of interventions across contexts. Such extrapolation has been recently undetaken for 71 the RTS,S/AS01 vaccine [11,12] and the endectocide ivermectin [13] for malaria. If failing to 72 account for such transmission dynamics contributes to an underestimated biological effect of 73 *Wolbachia* on DENV, we risk incorrectly assessing its broader impact. Given the myriad 74 intervention options available to public health officials for dengue control [14], it is important for 75 the potential impacts of each to be understood as well as possible.

In this study, we used a mathematical model of DENV transmission to gain insight into the possible magnitudes of the three aforementioned sources of bias. Our approach involved translating model inputs of the basic reproduction number (R_0), the spatial scale of human

6

It is made available under a CC-BY 4.0 International license .

7

79 movement (b), and the proportional reduction in R_0 afforded by Wolbachia-infected mosquitoes (ε) into outputs of the infection attack rate (IAR) in control and treatment arms of a trial, in 80 81 accordance with a seasonal, two-patch susceptible-infectious-recovered (SIR) model [15]. We 82 used the outputs of IAR in treatment and control arms (IAR, and IAR, respectively) to obtain an 83 estimate of the odds ratio (OR) of infection and, thereby, an estimate of the efficacy of the 84 intervention, Eff = 1 - OR. We constructed six different model versions for estimating efficacy. 85 each of which includes different combinations of the three biases, all of them, or none of them. 86 Henceforth, we refer to the efficacy observed in the AWED trial as "observed efficacy," and the 87 efficacy estimated by a given model and ε as "estimated efficacy." Finally, we quantify each bias 88 as the difference in the efficacy estimated by a model including that bias and a model which 89 does not include that bias (see Methods for more details of our methods).





Fig. 1: The spatial scales of transmission and trial design. A: Idealized trial design. We
 used a checkerboard pattern to approximate the design of the AWED trial of Wolbachia-infected

94 mosquitoes to control dengue [7]. ρ_{ii} represents the amount of time an individual who lives in

95 arm i spends in arm j, where i and j can represent either control (c) or treatment (i). b describes

It is made available under a CC-BY 4.0 International license .

9

96 the scale of human movement. B: The relationship between the scale of human movement and 97 the amount of time individuals spend in clusters of the same type as their home cluster. C: The 98 relationship between the reduction in R_0 (ϵ) required to reproduce the observed efficacy in the 99 AWED trial and the time people spend in their allocated arm. In this panel and panels E and F. 100 the dark blue line corresponds to the observed mean estimated in the AWED trial whereas the 101 light blue line and shaded region correspond to the 95% confidence intervals. D: The 102 relationship between ε and the estimated efficacy when b = 60 m. The black line shows the 103 theoretical relationship between a reduction in R_0 and observed efficacy, assuming no mosquito 104 movement and no human movement between arms. The blue line shows this relationship if we 105 include these two factors as well as the effect of transmission coupling. The dark and light blue 106 squares indicate the mean and the 95% confidence interval respectively of the observed 107 efficacy in the AWED trial and the corresponding reduction in R_0 . E: The relationship between 108 the amount of time people spend in their allocated arm and the estimated efficacy. F: The relationship between the size of the clusters and the estimated efficacy. The dashed line 109 110 indicates the estimated efficacy at the baseline cluster size (1000m). In all panels, parameters 111 are at their baseline given in Table S1 unless otherwise stated.

112

113 Results

114 We assumed a checkerboard pattern of control and treatment arms of 1 km² to

approximate the design used in the AWED trial, which covered the entire city of Yogyakarta,

116 with neighboring areas assigned to one arm or another in an (approximately) alternating pattern

117 (Fig. 1A) [7], and assume that individuals are evenly distributed within each cluster such that

they have no internal spatial structure. The time that humans spend away from their home is

assumed to follow a Laplace distribution (Fig. 1A, top right), which takes a single parameter, *b*,

120 that we refer to as the scale of human movement. By assuming that individuals are evenly

121 distributed within each cluster, we can then estimate the average proportion of time that

122 individuals in each trial arm spend in their own arm (ρ_{tt} and ρ_{cc}) and in the opposite arm (ρ_{tc} and

123 ρ_{ct} – see the Apportionment of time at risk section in Methods for details). Larger values of b

imply that people spend less time in their allocated arm, and for large values of *b* individuals

spend roughly equal amounts of time in both arms (Fig. 1B).

126 The relationship between the efficacy estimated by the model with all three forms of bias 127 (the estimated efficacy) and the reduction in R_0 (ε) was dependent on the amount of time people 128 spent in their allocated arm (Fig. 1C)—the less time individuals spent in their allocated arm, the 129 higher the reduction in R_0 that was needed to recreate the observed efficacy from the AWED

It is made available under a CC-BY 4.0 International license .

11

130 trial. If individuals spent less than 83.9% of their time in their allocated arm, it was impossible to 131 generate the observed efficacy (77.1%), as that would have implied that ε exceeded 1. 132 Assuming that individuals spent 92.9% of their time in their allocated arm (i.e., $\rho_{ii} = 92.9\%$, 133 corresponding to b = 36.9 m - see the Spatial Scale of Human Movement section in Methods 134 for details and justification), we found that the observed efficacy (77.1% [95% CI: 65.3% -135 84.9%]) corresponded to an ε of 49.9% (95% CI: 30.8% - 73.1%) (Fig. 1D, blue line). If we 136 instead assumed that there was no movement between trial arms, we observed that much 137 smaller values of ε were needed to explain the observed efficacy (6.3% [95% CI: 4.8% - 8.1%]). 138 The difference between these estimates provides an indication of the extent of bias introduced 139 by assuming that humans and mosquitoes remain in their allocated arms, when they in fact do 140 not (Fig. 1D).

141 When we fixed ε to the value that reproduces the observed efficacy in the AWED trial 142 and increased human movement between arms by increasing b, the estimated efficacy by the 143 model accounting for all three forms of bias decreased (Fig. 1E). For example, increasing the 144 average distance in one direction between transmission pairs (b) from 36.9 m to 70 m caused a 145 relative reduction of 20.0% in estimated efficacy, highlighting the sensitivity of efficacy to the 146 spatial scale of human movement. This effect occurs for two reasons: first, as people spend less 147 time in their allocated arm, the proportion of time that people spend under the intervention 148 becomes more similar between arms; and secondly, in the presence of transmission coupling, a 149 reduction in prevalence in the intervention arm reduces transmission in the control arm more as 150 people spend less time in their allocated arm. Relatedly, estimated efficacy depended on the 151 dimensions of the trial clusters, which we set to 1 km² by default (Fig. 1F). When we reduced 152 the cluster dimensions to 500 m x 500 m, estimated efficacy dropped from 77.1% to 60.3%, 153 representing a 21.8% relative reduction. This effect occurs because, as the cluster dimensions 154 are reduced, people spend less time in their home cluster. Hence, the time spent in each trial 155 arm approaches parity (i.e., 50%). Increasing cluster dimensions above 1 km² had somewhat

12

It is made available under a CC-BY 4.0 International license .

13

156 less of an effect on estimated efficacy. For example, increasing the cluster dimensions to 2 km x
157 2 km resulted in an estimated efficacy of 86.7%, a relative increase of 12.4%.

158 Our approach enabled us to directly and separately model each of the three potential 159 sources of bias: (1) mosquito movement, (2) human movement, and (3) transmission coupling. 160 Movement of Wolbachia-infected mosquitoes is modeled by including a time-varying level of 161 coverage, and we assume that mosquito movement does not contribute to DENV transmission 162 (See Methods - wMel coverage). When we assumed that ε was equal to 49.9%, allowing for 163 mosquito movement but not human movement produced an estimated efficacy of 99.1%. 164 because there was almost no transmission in the intervention arm in that case (Fig. 2A, Fig. 165 S7). If we allowed for both mosquito movement and human movement, we observed a lower 166 estimated efficacy of 93.6%. Although there was little transmission in the intervention arm in this 167 case, individuals residing in the intervention arm could be infected in the control arm. 168 Additionally, those assigned to the control arm experienced lower overall risk due to their time 169 spent in the intervention arm. When we accounted for transmission coupling between trial arms 170 alongside human and mosquito movement, thereby allowing for more transmission in the 171 intervention arm, risk was the most similar across the trial arms of all scenarios, leading to the 172 lowest estimated efficacy of 77.1% for an ε equal to 49.9%.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266602; this version posted December 20, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license.



Reduction in R_0 (%), ε

173

174 Fig. 2: Sources of bias in efficacy estimates. In both panels, yellow refers to mosquito 175 movement, red to human movement, and blue to transmission coupling. A: The relationship between the reduction in R_0 (ϵ) and the estimated efficacy for the six possible models. The black 176 177 line here is the relationship for a model with no human movement or mosquito movement. 178 Where a line has more than one color, it represents the model which includes each of the types 179 of bias represented by those colors. The difference between this line and each of the colored 180 lines represents the bias introduced by not accounting for the features present in the model 181 described by that colored line. B: the contribution of each source of bias to the total bias. Eff[®] refers to the estimated efficacy from a model with none of the biases. Eff^(h) to the estimated 182 efficacy from a model with human movement only, Eff^(m) to the estimated efficacy from a model 183 with mosquito movement only, Eff^(hm) to the estimated efficacy from a model with human and 184 mosquito movement, Eff^(ht) to the estimated efficacy from a model with human movement and 185 transmission coupling, and Eff^(hmt) to the estimated efficacy from a model with all three biases. 186 187

We guantified total bias as *Eff^(hmt)* - *Eff⁽⁰⁾*, where *Eff^(hmt)* is the estimated efficacy under the 188

model with all sources of bias and *Eff*⁽⁰⁾ is the estimated efficacy under the model without human 189

190 or mosquito movement. We then computed the difference in the bias produced by pairs of

It is made available under a CC-BY 4.0 International license.

17

191 models to decompose overall bias into each of its three sources (Fig. 2B, Fig. S8-9, see 192 *Methods* for details). At the baseline ε of 49.9%, 17.6% of the total bias was attributable to 193 mosquito movement, 8.3% to human movement, and 74.1% to transmission coupling. At all 194 values of ε , the greatest source of bias was transmission coupling between trial arms. When ε 195 was below a value of around 10%, the effective reproduction number at the start of the trial 196 exceeded 1 in both arms. This value of ε varied slightly based on the model used (Fig. S8-9). If 197 ε was below this critical value, increasing it in the context of coupled transmission reduced 198 incidence in the control arm and caused smaller reductions in incidence in the intervention arm 199 than if transmission had been uncoupled (Fig. S7, e.g. panels D vs. F). This implies that the bias 200 introduced by transmission coupling increases as ε increases up to ~10% under our model's parameterization (Fig. 2B). Increasing ε past this point only leads to small reductions in 201 202 incidence in the intervention arm in an uncoupled model, as incidence is already very low.

203

204 Discussion

205 Our results highlight three sources of bias (human movement, mosquito movement, and 206 transmission coupling) that arise in large, cluster-randomized, controlled trials of interventions 207 against mosquito-borne diseases, and have implications for how to mitigate these biases. 208 Biases arising due to human movement and mosquito movement are typically able to be 209 addressed through careful statistical analysis of trial data or in the design of the trial [8]. For 210 instance, in the per-protocol analysis of the AWED trial, Utarini et al. accounted for these two 211 forms of bias by combining self-reported recent travel and local Wolbachia prevalence into an 212 individual-level Wolbachia exposure index [7]. Comparing groups with the highest and lowest 213 *Wolbachia* exposure did not lead to higher efficacy estimates than their primary analysis. 214 Another approach to addressing contamination involves describing the effectiveness of the 215 intervention at the boundary between clusters using a sigmoid function [16–18]. Our results 216 suggest that failure to take steps such as this to account for human and mosquito movement

18

19

It is made available under a CC-BY 4.0 International license .

would typically lead to underestimated efficacy, while failure to account for transmission
coupling would lead to an even greater underestimate, particularly at intermediate reductions in *R*₀.

220 Bias arising from human and mosquito movement could also be mitigated at the stage of 221 planning the trial. The classical design to achieve this is the 'fried-egg' design, in which a treated 222 buffer-zone is placed between intervention and control clusters [19]. A more recently proposed 223 approach involves excluding a subset of clusters from the trial completely, thereby increasing 224 the distance between clusters and leading to disconnected clusters at less risk of contamination 225 [20]. While both of these approaches do mitigate the risk of contamination directly, they also 226 necessitate a larger trial area and may be logistically infeasible in a trial taking place in a single 227 city, as was the case for the AWED trial. Another approach could include reducing the number 228 of clusters, but keeping the total area fixed, leading individuals to spend more time in their 229 assigned arm and reducing mosquito movement by reducing the boundary between clusters. 230 Our results show that the efficacy estimated from cluster-randomized, controlled trials of 231 interventions against mosquito-borne diseases is highly sensitive to cluster size (Fig. 1F). Had 232 the dimensions of the clusters in the AWED trial been much smaller, then the estimated efficacy 233 may have been substantially lower. However, having fewer, yet larger clusters would likely 234 introduce new biases by making the arms less comparable, which may not be an acceptable 235 trade-off.

While bias due to human and mosquito movement can be mitigated through trial design and statistical methods, our results highlight a third source of bias, transmission coupling, that requires additional tools to fully address. Accounting for this bias first requires data on the spatial distribution of the intervention and on human movement, similar to that used in the supplementary analysis of the AWED trial. However, it also requires interfacing these data with a dynamical transmission model to account for the fact that, in the presence of movement between arms, incidence in each arm depends on prevalence in both arms [21]. Many common

20

It is made available under a CC-BY 4.0 International license.

21

243 trial designs will lead to reduced bias due to transmission coupling - for instance by allocating 244 a greater proportion of the trial area to the control arm, with small intervention clusters situated 245 among larger control clusters so that transmission suppression in the intervention arm has less 246 of a population-level effect. The ratio of area allotted to treatment and control would depend on 247 many factors, including the expected strength of the intervention, the local force of infection, and 248 logistical constraints such as the size and length of the trial. Utilizing a dynamical model 249 synthesizing these factors in the design of a trial could aid in understanding how different 250 designs might affect bias due to transmission coupling [21]. More work is needed to understand 251 what types of spatial clustering patterns, among other features of trial design, would minimize 252 this form of bias.

253 Although our modeling approach allowed us to account for different potential sources of 254 bias and to attribute the total bias to each of those sources, it has at least four limitations. First, 255 our model was deterministic, yet stochasticity could be important for a highly efficacious 256 intervention with potential to reduce transmission to very low levels [22]. This simplification 257 implies that our estimates are likely conservative, as these effects could increase the bias due 258 to transmission coupling if a highly effective intervention increases the probability of 259 transmission fadeouts. Second, our simple model does not reflect all of the complexities of 260 DENV transmission. For example, we did not account for spatial heterogeneities in transmission 261 or interactions between serotypes. Accurately quantifying the contribution of these effects to 262 bias would require a more detailed model, but the qualitative results would likely be similar. 263 Third, we did not calibrate our model to trial data, so incidence in our model may not reflect the 264 actual incidence during the trial. However, our aim here was not to precisely quantify bias in the 265 AWED trial, but rather to highlight some potential sources of bias in trials of that nature and to 266 understand how these biases are influenced by transmission dynamics and human mobility. 267 Moreover, our model was calibrated to actual incidence from past years in Yogyakarta, and so 268 still reflects transmission typical of that location. It is also worth noting that an earlier version of

22

It is made available under a CC-BY 4.0 International license .

the manuscript, which used a simpler static model based on epidemic attack rate formulae, had
qualitatively similar findings [23]. Finally, we don't account for heterogeneity between clusters,
such as regions of the city with systematically higher mosquito abundance, or greater human
movement, or within clusters, such as that transmission may be higher at the edge of control
clusters.

274 In conclusion, without accounting for human movement, mosquito movement, and 275 transmission coupling, the efficacy of Wolbachia-infected mosquitoes as an intervention to 276 control dengue is likely to be underestimated. As the estimate of efficacy in the AWED trial was 277 already very high (77.1% [95% CI: 65.3% - 84.9%]) [7] and, as we show, likely underestimated, 278 Wolbachia-infected mosquitoes have potential to be a game-changing tool in the fight against 279 dengue. Even as vaccines against dengue become available, a variety of vector control 280 approaches are likely to remain key tools in the fight against dengue [2,14]. Although we 281 focused our study on a trial of *Wolbachia*-infected mosquitoes, our findings are applicable to any 282 efficacy trial of an intervention that has the potential to contaminate the control arm, such as 283 gene drive mosquitoes or ivermectin as interventions against malaria [24,25]. As trials of these 284 interventions continue, it will be important to learn what lessons we can from transmission 285 dynamic modeling when designing and interpreting future trials to ensure that we understand 286 the true promise of these interventions.

287

23

288 Methods

289 Transmission model

We simulated DENV transmission using a four-serotype, two-patch seasonal SIR model. In this model, fully susceptible individuals may become infected with any of the four serotypes. Once infected, individuals have an exponentially-distributed period of cross-immunity to all other serotypes with a mean of two years. Individuals with prior exposure to one or more serotypes but that are not currently in their period of cross-immunity are immune to the serotypes they

24

It is made available under a CC-BY 4.0 International license .

25

have previously been infected with. We implicitly assume that all four serotypes circulate in equal proportions. Births and deaths are modeled so that the population size remains constant, and the mortality rate is the reciprocal of the mean life expectancy, taken from the United Nations World Population Prospects database [26]. The transmission parameter, $\beta(t)$, varies seasonally according to a sine curve with a period equal to one year. The model equations are as follows, with parameter definitions and values given in Tables S1 and S2, and the model diagram is shown in Fig. S1.

302
$$\frac{dS_0}{dt} = \mu (1 - S_0) - P \times (1 - \epsilon C(t)) \beta(t) \frac{I}{N} S_0$$

303
$$\frac{dI_1}{dt} = P \times (1 - \epsilon C(t))\beta(t)\frac{I}{N}S_0 - (\gamma + \mu)I_1$$

$$\frac{dR_1}{dt} = \gamma I_1 - (\omega + \mu)R_1$$

305
$$\frac{dS_1}{dt} = \omega R_1 - P \times (1 - \epsilon C(t)) \beta(t) \frac{3}{4} \frac{I}{N} S_1 - \mu S_1$$

306
$$\frac{dI_2}{dt} = P \times (1 - \epsilon C(t))\beta(t)\frac{3}{4}\frac{I}{N}S_1 - (\gamma + \mu)I_2$$

$$\frac{dR_2}{dt} = \gamma I_2 - (\omega + \mu)R_2$$

308
$$\frac{dS_2}{dt} = \omega R_2 - P \times (1 - \epsilon C(t)) \beta(t) \frac{1}{2} \frac{I}{N} S_2 - \mu S_2$$

309
$$\frac{dI_3}{dt} = P \times (1 - \epsilon C(t))\beta(t)\frac{1}{2}\frac{I}{N}S_2 - (\gamma + \mu)I_3$$

310
$$\frac{dR_3}{dt} = \gamma I_3 - (\omega + \mu)R_3$$

311
$$\frac{dS_3}{dt} = \omega R_3 - P \times (1 - \epsilon C(t))\beta(t)\frac{1}{4}\frac{I}{N}S_3 - \mu S_3$$

312
$$\frac{dI_4}{dt} = P \times (1 - \epsilon C(t))\beta(t)\frac{1}{4}\frac{I}{N}S_3 - (\gamma + \mu)I_4$$

It is made available under a CC-BY 4.0 International license .

$$\frac{dR_4}{dt} = \gamma I_4 - \mu R_4$$

314
$$I = I_1 + I_2 + I_3 + I_4$$

315
$$\beta(t) = \beta_0 (1 + \beta_a \sin(\frac{2\pi(\theta + t)}{365.25}))$$
 (S1)

317 Table S1. Model parameter values

Symb ol	Definition	Value	Source
μ	Mortality rate (day ⁻¹)	1/(71.4 x 365.25)	UN World Population Database [26]
ε	Transmission reduction due to Wolbachia	varied	N/a
Р	A 2x2 matrix describing the proportion of time people spend in their home and non-home patches	varied	See Model parameterization section
C(t)	A 1x2 vector describing the time-varying coverage of <i>Wolbachia</i> in each patch	See Fig. S6	Utarini et al. [7]
Y	Recovery rate (day ⁻¹)	1/7	Burattini et al. [27]
ω	Waning rate of cross-immunity (day-1)	1/(2 x 365.25)	Reich et al. [28]
R ₀	Basic reproduction number	3.21	See Model parameterization section
α	Amplitude in rate of effective contact	<i>calibrated</i> bounds: (0, 0.2) estimate: 0.0588	N/a
θ	Offset in seasonality (days)	<i>calibrated</i> bounds: (0, 180) estimate: 77.8	N/a
υ	Proportion of infections reported as cases	<i>calibrated</i> bounds: (0.01, 0.2) estimate: 0.0601	N/a

Table S2. All state variables are 1x2 vectors describing the number in each of the two patches.

It is made available under a CC-BY 4.0 International license .

29

Symbol	Definition
S _i	Number of susceptible individuals with <i>i</i> prior infections
I	Number of infectious individuals with <i>i</i> prior infections
R _i	Number of immune individuals with <i>i</i> prior infections; individuals in this group are immune to all serotypes until their cross-immunity wanes



322 Fig. S1: Model diagram. The superscripts refer to the number of times individuals in that 323 compartment have been infected. Susceptible individuals (Si) experience a reduced force of 324 infection according to the number of prior infections they have experienced. We assume all 325 serotypes circulate equally. Following infection, individuals experience a temporary period of 326 immunity to all serotypes (R_i). Mortality occurs at an equal rate from all compartments and is not

It is made available under a CC-BY 4.0 International license .

31

327 shown.

328 Transmission model calibration

329 We calibrated the model to data on reported cases of dengue fever over a ten year period [29]

330 (Fig. S2). We first averaged the monthly number of reported cases, to capture the average

dynamics across the period. We ran the model for 100 years to reduce the influence of initial

332 conditions, and then fitted model years 101-110 to the 10 average years from the data using

333 maximum likelihood. We used a Poisson likelihood function,

334
$$L(x_{model}, v | x_{data}) = \frac{(x_{model} v)^{x_{data}} e^{-x_{model} v}}{x_{data}!},$$
(S2)

where x_{model} is the number of infections per month predicted by the model and x_{data} is the number of cases per month in the data.



337

Fig. S2: Model calibration. Calibration of seasonal SIR model to data on dengue cases from
Yogyakarta. The faint red line and points show the data on the monthly number of cases from
2006 to 2017 in Yogyakarta, taken from Indriani et al. [29]. The solid red lines and points show
this data average by month. The gray polygon shows the model calibrated to the average
number of monthly cases.

It is made available under a CC-BY 4.0 International license .

33

343

344 Efficacy models

Let ε represent the effectiveness of the intervention, defined as the proportional reduction in the pre-intervention basic reproduction number, R_0 , when the intervention is applied at full coverage in a treatment cluster. Hence, in the absence of human or mosquito movement,

348

349	$R_{0} = (1-\varepsilon)R_{0}$	(S3)
545	$\mathbf{n}_{0,t} - (1 \mathbf{c}) \mathbf{n}_0$	(33)

- 350 $R_{0,c} = R_0.$ (S4)
- 351

352 Our interest is in quantifying the infection attack rate (IAR), π , within each cluster during a trial. 353 To do this, we simulate the model for two years, and calculate the infection attack rate in each 354 arm during that time. We estimate the initial proportion in each compartment by first simulating 355 the model for 100 years. We do this with six different models that include combinations of three 356 different types of bias: human movement between arms, mosquito movement between arms, 357 and transmission coupling between arms. The six resulting models are described below (note 358 that transmission coupling can only occur in the presence of human movement). Each model is 359 defined by different values for P and C(t).

360

361 **1. No bias**

In the absence of contamination from human movement or mosquito movement between arms, we can essentially use equations (S3) and (S4) to describe the reproduction in each arm. This amounts to setting C(t) = (1, 0) and P = I, the identity matrix.

365

366 2. Bias from mosquito movement

367 We represent the coverage of the intervention—i.e., the proportion of Wolbachia-infected

It is made available under a CC-BY 4.0 International license .

35

368 mosquitoes—in the two arms with $C_{\rm t}(t)$ and $C_{\rm c}(t)$. In the case of mosquito movement, there may 369 be non-zero coverage of intervention in the control arm (i.e., $C_c>0$), and less than 100% 370 coverage in the treatment arm (i.e., $C_t < 1$). Hence we set $C(t) = (C_c(t), C_t(t))$ and P = I. 371 Here we are assuming that movement of mosquitoes between trial arms does not 372 directly contribute to DENV transmission via movement of DENV-infected mosquitoes. This 373 discrepancy can be reconciled by the fact that the spread of dengue virus occurs within a single 374 mosquito generation, whereas the spread of Wolbachia occurs over the course of multiple 375 generations. 376

377 3. Bias from human movement

Let ϱ_{ij} represent the ijth element of P,—i.e., the proportion of the total time at risk that a resident of cluster *i* spends in cluster *j*. To account for human movement, but no transmission coupling, we set $C(t) = (\varrho_{ct}, \varrho_{tl})$ and P = I. This is because in this scenario, the wMel coverage in the treatment arm is 1, and in the control arm is 0, so the experienced wMel exposure reduces to the time spent in the treatment arm.

383

384 4. Bias from human movement and mosquito movement

385 We now have both human and mosquito movement, so we set

386 $C(t) = (\varrho_{cc}C_c(t) + \varrho_{ct}C_t(t), \varrho_{tc}C_c(t) + \varrho_{tt}C_t(t)), \text{ and } P = I. \text{ Note that, by definition, } \varrho_{tt} + \varrho_{tc} = 1 \text{ and } \varrho_{cc} +$ 387 $\varrho_{ct} = 1.$

388

389 **5.** Bias from human movement and transmission coupling

Thus far, we have assumed that transmission in each arm is only a function of prevalence in that arm, and not in the other. To relax this assumption, we couple transmission between the two arms by varying P. In the presence of human movement but not mosquito movement, we set C = (0, 1) and P = (ϱ_{cc} , ϱ_{ct} ; ϱ_{tc} , ϱ_{tt}).

It is made available under a CC-BY 4.0 International license.

37

394

395 6. Bias from human movement, mosquito movement, and transmission coupling

Finally, we include all three forms of bias by again setting P = (ϱ_{cc} , ϱ_{ct} , ϱ_{tc} , ϱ_{tt}), and

397 $C = (C_c(t), C_t(t)).$

398

399 Efficacy calculation

400 The ratio of the IARs in the treatment and control clusters is an infection risk ratio. However, the

401 AWED trial based their efficacy calculations upon an odds ratio [7], with symptomatic,

402 virologically-confirmed dengue as the end point. That is, efficacy in the trial was computed as 1-

403 $p_t n_c / p_c n_t$, where p_i and n_i represent enrolled test-positives and test-negatives, respectively, in trial

404 arm *i*. To generate a comparable quantity, we computed the efficacy according to model *x* as

405

406
$$Eff^{(x)} = 1 - \frac{\pi^{(x)}_{t}}{\pi^{(x)}_{c}} \frac{1 - \pi^{(x)}_{c}}{1 - \pi^{(x)}_{t}},$$
 (S5)

407

where $\pi^{(\aleph)}_{i}$ is the infection attack rate in trial arm $i \in \{c,t\}$ for model $x \in \{0,h,m,hm,ht,hmt\}$. Here, we are assuming that the ratio of infections to enrolled test-positives does not differ between arms (i.e., $p_i = k_p \pi_i$ for $i \in \{c,t\}$) and similarly the ratio of those uninfected to enrolled test-negatives also does not differ between arms (i.e., $n_i = k_n(1 - \pi_i)$ for $i \in \{c,t\}$). If either of these assumptions were violated, for instance if the intervention affected either the proportion of dengue infections that were symptomatic, then our estimate of efficacy would be less comparable to the estimate used in the AWED trial.

415

416 Bias calculation

We calculated the bias due to a particular source as the difference in the efficacy between amodel with that source of bias and a model without that source of bias. As biases appear in

It is made available under a CC-BY 4.0 International license .

39

419 multiple models, this led to three ways to embed the models, and three corresponding ways to 420 quantify each bias. The three embeddings are: A) no bias \rightarrow mosquito movement \rightarrow human 421 movement + mosquito movement \rightarrow full model; B) no bias \rightarrow human movement \rightarrow human 422 movement + mosquito movement \rightarrow full model; and C) no bias \rightarrow human movement \rightarrow human 423 movement + transmission coupling \rightarrow full model. The difference between efficacy estimates for 424 adjacent models in an embedding will lead to an expression for the bias which differs between 425 the two models. Hence, the three possible ways to calculate each of the three sources of bias 426 yields 427 bia $s^{(m)}_{A} = Ef f^{(m)} - Ef f^{(0)}$ 428 (S6A) bia $s^{(m)}_{B} = Ef f^{(hm)} - Ef f^{(h)}$ 429 (S6B) bia $s^{(m)}_{\ C} = Eff^{(hmt)} - Eff^{(ht)}$ 430 (S6C) $bia s^{(h)}_{A} = Ef f^{(hm)} - Ef f^{(m)}$ 431 (S7A)

- $bia s^{(h)}_{B} = Ef f^{(h)} Ef f^{(0)}$ 432 (S7B)
- bia $s^{(h)}_{C} = Ef f^{(h)} Ef f^{(0)}$ 433 (S7C) bia $s^{(t)}_{A} = Ef f^{(hmt)} - Ef f^{(hmt)}$
- bia $s^{(t)}_{B} = Eff^{(hmt)} Eff^{(hmt)}$ 435 (S8B)

436
$$bia s^{(t)}_{C} = Ef f^{(ht)} - Ef f^{(h)}$$
. (S8C)

437

434

438 We then calculate the average total bias caused by each source of bias as

439
$$bia s^{(i)} = \frac{\sum_{j \in [A,B,C]} bia s^{(i)}_{j}}{3},$$
 (S9)

440

where $i \in \{h, m, t\}$. Note that $bias^{(t)} = bias^{(t)} and bias^{(h)} = bias^{(h)} c$, but it is necessary to include each 441

(S8A)

It is made available under a CC-BY 4.0 International license .

41

442 as a separate term so that each of the three model embeddings is included equally.

443

444 Model Parameterization

445 Apportionment of Time at Risk

446 We considered a checkerboard arrangement for the treatment and control clusters in a trial

447 across a two-dimensional landscape (Fig. 1A, Fig. S10). Under this scenario, we assume that

the population density per unit area is constant and that transmission potential, as captured by

449 R_0 , is homogeneous across the landscape prior to initiation of the trial.

450 At the core of this derivation is the assumption that the location where an individual *j*

451 resides who was infected by an individual *i* is determined by an isotropic transmission kernel,

452 $k(|x_i - x_j|, |y_i - y_j|)$, where x and y are the spatial coordinates for the residence of each of *i* and

453 *j*. We use a Laplace distribution with marginal density functions for each of the *x* and *y*

454 coordinates,

455

456
$$k(x_{j}|\mu=x_{i},b)=\frac{1}{2b}e^{\frac{-|x_{j}-\mu|}{b}}$$
 (S10)

457
$$k(y_{j}|\mu=y_{i},b)=\frac{1}{2b}e^{\frac{-|y_{i}-\mu|}{b}}.$$
 (S11)

458

where μ is the location parameter and *b* is the scale parameter [30]. The scale parameter *b* is equal to the average distance in one direction between the locations where infector and infectee reside.

462 Under the checkerboard arrangement, we considered alternating squares of width δ 463 corresponding to treatment and control clusters within a contiguous urban area (Fig. 1A). 464 Although any such area would have borders in reality, we ignored any possible edges effects 465 and assumed that the extent of interactions between squares of type *t* and *c* in the interior of the

It is made available under a CC-BY 4.0 International license .

43

466checkerboard provide a suitable characterization of overall interaction between individuals467residing in t and c, as summarized by
$$\rho_{it}$$
 and ρ_{cc} . Because the area and arrangement of t and c468squares are identical, $\rho_{\pi} = \rho_{cc}$ and $\rho_{\pi} = \rho_{cc}$ (Fig. 1A).469We approach this problem by first calculating the proportion of time at risk that an470individual *i* residing on a line within in an interval of width $\delta = \mu_{tr} \mu_{t}$ experiences in an adjacent471interval of width Δ. Let the former interval span [$\mu_{t}\mu_{t}$] and the latter interval span [$\mu_{t}\mu_{t}+\Delta$]. If *i*472resides specifically at μ , then the proportion of its time at risk in the other interval is473 $F(\mu_{t}+\Delta|\mu,b)-F(\mu_{t}|\mu,b)$. (S12)474 $A_{\delta,a} = \frac{1}{\delta} \int_{\mu_{t}}^{\mu} (F(\mu_{t}+\Delta|\mu,b)-F(\mu_{t}|\mu,b)) d\mu$. (S13)479 $A_{\delta,a} = \frac{1}{\delta} \int_{\mu_{t}}^{\mu} (F(\mu_{t}+\Delta|\mu,b)-F(\mu_{t}|\mu,b)) d\mu$. (S13)480which gives the proportion of time in the interval of length Δ for an individual who resides in the481which gives the proportion of time in the Laplace distribution function is $F(x|\mu,b)=1-\frac{1}{2}\exp(-(x-\mu)/b)$

483 when $x > \mu$, eqn. (S25) evaluates to

484

485
$$A_{\delta,\Delta} = \frac{b}{2\delta} (1 - e^{-\delta/b} - e^{-\Delta/b} + e^{-(\delta + \Delta)/b}).$$
(S26)

486

487 We can quantify the proportion of time at risk in the interval of width δ for individuals who reside 488 there as

It is made available under a CC-BY 4.0 International license .

45

490
$$A_{\delta} = 1 - 2 \lim_{\Delta \to \infty} A_{\delta,\Delta} = 1 - \frac{b}{\delta} (1 - e^{-\delta/b}).$$
(S14)

491

We also need to calculate the time at risk in a non-adjacent interval of width δ_3 whose edge is spaced distance δ_2 away from the nearest edge of the interval where the individual resides, which has width δ_1 . Applying similar reasoning as in eq. (S25), we obtain

495

496
$$A_{\delta_1,\delta_2,\delta_3} = \frac{b}{2\delta_1} \left(e^{-\delta_2/b} - e^{-(\delta_1 + \delta_2)/b} - e^{-(\delta_2 + \delta_3)/b} + e^{-(\delta_1 + \delta_2 + \delta_3)/b} \right).$$
(S15)

497

We can calculate the proportion of time spent in like squares by applying the probabilities used to calculate the proportions of time at risk for residents who live under treatment or not. Going out three layers from a focal square (Fig. S10), the proportion of time spent in like squares is 501

502
$$B = A_{\delta}^{2} + 4 A_{\delta,\delta}^{2} + 4 A_{\delta,\delta,\delta} A_{\delta} + 4 A_{\delta,\delta,\delta}^{2} + 8 A_{\delta,2\delta,\delta} A_{\delta,\delta} + 4 A_{\delta,2\delta,\delta}^{2}, \qquad (S16)$$

503

and the proportion of time spent in unlike squares is

505

506
$$C = 4 A_{\delta,\delta} A_{\delta} + 8 A_{\delta,\delta,\delta} A_{\delta,\delta} + 4 A_{\delta,2\delta,\delta} A_{\delta} + 8 A_{\delta,2\delta,\delta} A_{\delta,\delta,\delta}.$$
 (S17)

507

508 The total proportion of time under treatment or not is then

509

510
$$\rho_{cc} = \rho_{tt} = \frac{B}{B+C}$$
(S18)

511
$$\rho_{tc} = \rho_{ct} = \frac{C}{B+C}.$$
 (S19)

512

It is made available under a CC-BY 4.0 International license .

47

513 Hence, for a checkerboard arrangement of clusters, the proportion of time which each individual 514 spends in each arm of the trial is uniquely determined by the width of each cluster (δ) and the 515 scale of human movement (*b*).

516

517 Calculation of Initial Susceptibility, force of infection, and R₀

518 To obtain an estimate of initial susceptibility, we followed ten Bosch et al. [31] and calculated the

proportion of the population exposed to *n* serotypes, $\forall n \in \{0, 1, 2, 3, 4\}$, as a function of age.

520 Following ten Bosch *et al.* [31], we defined $e_i(a)$ as the proportion of individuals of age *a* that

have been exposed to *i* serotypes and $r_i(a)$ as the proportion of individuals of age *a* experiencing

522 temporary heterologous immunity following exposure to *i* serotypes. The dynamics of how

523 individuals progress through these classes as they age follows

524

525
$$\frac{d e_0}{da} = -4\Lambda e_0 \tag{S20}$$

526
$$\frac{dr_i}{da_{i=1,..,4}} = (4 - (i-1))\Lambda e_{(i-1)} - \sigma r_i$$
(S21)

527
$$\frac{d e_i}{da_{i=1,..,4}} = \sigma r_i - (4-i) \Lambda e_i.$$
 (S22)

528

529 In eqs. (S33-S35), Λ = 0.0457 is the force of infection, and σ is the rate at which individuals lose 530 heterologous immunity, which we set to 0.5/yr [31].

We computed the proportion of the population in Yogyakarta, Indonesia that is of age *a* using estimates from the United Nations World Population Prospects database [32] and computed the proportion of the population that is susceptible to their (i+1)th infection as

535
$$E_i = \sum_{a} (p(a)e_i(a)).$$
 (S23)

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266602; this version posted December 20, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . 49 536 537 It follows that initial susceptibility is equal to 538 539 $S' = E_0 + \frac{3}{4}E_1 + \frac{1}{2}E_2 + \frac{1}{4}E_3$, (S24) 540 541 provided that the force of infection for each serotype has been constant over time. For the 542 assumed values of Λ and σ , S' = 0.341 for Yogyakarta, Indonesia.

- 543 We used data on seropositivity by age from Yogyakarta [29] to estimate the mean
- annual force of infection using the above catalytic model (Fig. S3). This led to an estimate of the
- 545 mean annual per-serotype force of infection of 0.0457.



546

Fig. S3: Force of infection estimation. The circles show the proportion of individuals that are
seropositive by age group in Yogyakarta, and the thin vertical lines show the 95% binomial
confidence intervals, both from Indriani et al. [29]. The thick black line shows the proportion that
would be expected to be seropositive according to the catalytic model with a per-serotype force
of infection of 0.0457.



It is made available under a CC-BY 4.0 International license .

53

553
$$R_0 = \frac{\log(S_f) - \log(S')}{S_f - S'}, \qquad (S25)$$

where S_t is the proportion susceptible after an outbreak. Here we estimate R_0 based on one season's transmission, i.e., $S_f = S' \exp(-4\Lambda)$, yielding $R_0 = 3.21$. We incorporate this estimate of R_0 into the transmission model by assuming that the mean value of $\beta(t)$ (i.e. β_0) is related to R_0 by $\beta_0 = R_0 \gamma$, i.e. we assume that R_0 represents the number of secondary infections in a fully susceptible population in the absence of seasonality. It is likely that this leads to an overestimate of β_0 , though our model still accurately recreates the typical epidemic peaks and troughs of Yogyakarta (Fig. S2).

561

562 Spatial Scale of Human Movement

563 Our calculations of the apportionment of time at risk depend upon a value of b, the spatial scale 564 of human movement, a quantity that is challenging to parameterize. To do this, we first estimate 565 the relative risk (RR) of 100% wMel coverage compared to 0% wMel coverage, based on the 566 per-protocol analysis in Utarini et al. In that analysis, the authors estimated a weighted wMel 567 exposure level based on human movement diaries and local wMel frequency over time. This is 568 essentially the product of the *wMel* frequency in a location and the amount of time an individual 569 spent there, and then summed over all of the locations at which that individual spent time. They 570 then binned individuals into five equal width groups based on their exposure index and 571 calculated the RR of infection compared to the lowest exposure group (Fig. S4). To estimate the 572 RR of 100% exposure compared to 0%, we fit a logistic curve to the binned RR values (using 573 the midpoints of each bin) and calculate the RR of 100% compared to 0%. This yields a RR of 574 0.18, or equivalently an efficacy of 82%.



Fig. S4. Efficacy adjusted for human movement. Circles and associated confidence intervals
show the relative risk at different levels of the wMel exposure index compared to the [0, 0.2)
group, according to the per-protocol analysis in Utarini et al. [7]. The horizontal red lines show
the relative risk from the intention-to-treat analysis in the same paper. The dashed horizontal
indicates a relative risk of 1. The black line indicates a logistic curve fit to the estimates of
relative risk from the per-protocol analysis.

It is made available under a CC-BY 4.0 International license .

57

To inform our selection of *b*, we compared the model with all of the biases included to the one with only human movement and transmission coupling. We then selected a value of *b* which enabled us to select a single value of ε that would lead to 77% efficacy in the full model, and 82% efficacy in the model with human movement and transmission coupling (Fig. S5). This yielded a value of *b*=36.9m, corresponding to $\rho_{tt} = \rho_{cc} = 0.929$ and $\rho_{tc} = \rho_{ct} = 0.071$ for the checkerboard arrangement.



It is made available under a CC-BY 4.0 International license .

59

590 Fig. S5: Estimation of scale of human movement.

591

592 wMel coverage

When modeling mosquito movement between trial arms, we use data on the time-varying wMel coverage in each trial arm from the AWED trial [7]. We average across clusters within each arm to find the average coverage over time. As we don't explicitly model mosquitoes or their movement, these averaged time series are then used directly in the model. They are shown in Fig. S6 and are represented in the model by $C(t) = (C_c(t), C_t(t))$, where $C_c(t)$ is given in the left panel and $C_t(t)$ in the right. When mosquito movement is not modeled, C(t) = (0, 1), for all *t*.



599

Fig. S6. wMel frequency in the AWED trial [7]. Each thin gray line shows the wMel frequency
over time in one of the treatment (A) or control (B) clusters. The red line and points show the
average of these, which is what was used in the model.

61

604 References

- 605 1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496: 504–507.
- Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness or
 Evidence?: Systematic Review and Meta-analysis. PLoS Negl Trop Dis. 2016;10:
 e0004551.
- Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R. Defining challenges and
 proposing solutions for control of the virus vector Aedes aegypti. PLoS Med. 2008;5: e68.
- Ferguson NM, Kien DTH, Clapham H, Aguas R, Trung VT, Chau TNB, et al. Modeling the
 impact on virus transmission of Wolbachia-mediated blocking of dengue virus infection of
 Aedes aegypti. Sci Transl Med. 2015;7: 279ra37.
- 5. Anders KL, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Andari B, et al. The AWED
 trial (Applying Wolbachia to Eliminate Dengue) to assess the efficacy of Wolbachia-infected
 mosquito deployments to reduce dengue incidence in Yogyakarta, Indonesia: study
 protocol for a cluster randomised controlled trial. Trials. 2018. doi:10.1186/s13063-0182670-z
- Anders KL, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Andari B, et al. Update to the
 AWED (Applying Wolbachia to Eliminate Dengue) trial study protocol: a cluster randomised
 controlled trial in Yogyakarta, Indonesia. Trials. 2020. doi:10.1186/s13063-020-04367-2
- 623 7. Utarini A, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Ansari MR, et al. Efficacy of
 624 Wolbachia-infected mosquito deployments for the control of dengue. N Engl J Med.
 625 2021;384: 2177–2186.
- Reiner RC, Achee N, Barrera R, Burkot TR, Chadee DD, Devine GJ, et al. Quantifying the
 Epidemiological Impact of Vector Control on Dengue. PLOS Neglected Tropical Diseases.
 2016. p. e0004588. doi:10.1371/journal.pntd.0004588
- Stoddard ST, Morrison AC, Vazquez-Prokopec GM, Paz Soldan V, Kochel TJ, Kitron U, et
 al. The role of human movement in the transmission of vector-borne pathogens. PLoS Negl
 Trop Dis. 2009;3: e481.
- Kraemer MUG, Bisanzio D, Reiner RC, Zakar R, Hawkins JB, Freifeld CC, et al. Inferences
 about spatiotemporal variation in dengue virus transmission are sensitive to assumptions
 about human mobility: a case study using geolocated tweets from Lahore, Pakistan. EPJ
 Data Sci. 2018;7: 16.
- Penny MA, Galactionova K, Tarantino M, Tanner M, Smith TA. The public health impact of
 malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18
 month follow-up Phase III data and simulation models. BMC Med. 2015;13: 170.
- Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, et al. Public health
 impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic
 comparison of predictions from four mathematical models. Lancet. 2016;387: 367–375.

- 63
- Slater HC, Foy BD, Kobylinski K, Chaccour C, Watson OJ, Hellewell J, et al. Ivermectin as
 a novel complementary malaria control tool to reduce incidence and prevalence: a
 modelling study. Lancet Infect Dis. 2020;20: 498–508.
- Achee NL, Gould F, Perkins TA, Reiner RC Jr, Morrison AC, Ritchie SA, et al. A critical assessment of vector control for dengue prevention. PLoS Negl Trop Dis. 2015;9:
 e0003655.
- 648 15. Miller JC. A note on the derivation of epidemic final sizes. Bull Math Biol. 2012;74: 2125–
 649 2141.
- Multerer L, Glass TR, Vanobberghen F, Smith T. Analysis of contamination in cluster
 randomized trials of malaria interventions. Trials. 2021;22: 613.
- Multerer L, Vanobberghen F, Glass TR, Hiscox A, Lindsay SW, Takken W, et al. Estimating
 intervention effectiveness in trials of malaria interventions with contamination. Malar J.
 2021;20: 413.
- 18. Hawley WA, Terlouw DJ, Ter Kuile FO, Gimnig JE, Phillips-Howard PA, Hightower AW, et
 al. Community-wide effects of permethrin-treated bed nets on child mortality and malaria
 morbidity in western Kenya. Am J Trop Med Hyg. 2003;68: 121–127.
- 19. Hayes RJ, Moulton LH. Cluster Randomised Trials. CRC Press; 2017.
- 659 20. McCann RS, van den Berg H, Takken W, Chetwynd AG, Giorgi E, Terlouw DJ, et al.
 660 Reducing contamination risk in cluster-randomized infectious disease-intervention trials. Int
 661 J Epidemiol. 2018;47: 2015–2024.
- 462 21. Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, et al. Simulations
 a for designing and interpreting intervention trials in infectious diseases. BMC Med. 2017;15:
 a 223.
- 665 22. Britton T. Stochastic epidemic models: a survey. Math Biosci. 2010;225: 24–35.
- Cavany SM, Huber JH, Wieler A, Elliott M, Tran QM, España G, et al. Ignoring transmission
 dynamics leads to underestimation of the impact of a novel intervention against mosquitoborne disease. medRxiv. 2021; 2021.11.19.21266602.
- Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, et al. Efficacy and risk of
 harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a
 cluster-randomised trial. Lancet. 2019;393: 1517–1526.
- 5. James S, Collins FH, Welkhoff PA, Emerson C, Godfray HCJ, Gottlieb M, et al. Pathway to
 Deployment of Gene Drive Mosquitoes as a Potential Biocontrol Tool for Elimination of
 Malaria in Sub-Saharan Africa: Recommendations of a Scientific Working Group. Am J
 Trop Med Hyg. 2018;98: 1–49.
- 676 26. United Nations Publications. World Population Prospects 2019: Demographic Profiles.677 2020.
- Burattini MN, Chen M, Chow A, Coutinho FAB, Goh KT, Lopez LF, et al. Modelling the
 control strategies against dengue in Singapore. Epidemiol Infect. 2008;136: 309–319.

65

- 880 28. Reich NG, Shrestha S, King AA, Rohani P, Lessler J, Kalayanarooj S, et al. Interactions
 between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc
 682 Interface. 2013;10: 20130414.
- Indriani C, Ahmad RA, Wiratama BS, Arguni E, Supriyati E, Tedjo Sasmono R, et al.
 Baseline Characterization of Dengue Epidemiology in Yogyakarta City, Indonesia, before a
 Randomized Controlled Trial of Wolbachia for Arboviral Disease Control. The American
 Journal of Tropical Medicine and Hygiene. 2018. pp. 1299–1307. doi:10.4269/ajtmh.180315
- 688 30. Kot M, Lewis MA, van den Driessche P. Dispersal data and the spread of invading 689 organisms. Ecology. 1996;77: 2027–2042.
- 690 31. Ten Bosch QA, Clapham HE, Lambrechts L, Duong V, Buchy P, Althouse BM, et al.
 691 Contributions from the silent majority dominate dengue virus transmission. PLoS Pathog.
 692 2018;14: e1006965.
- 693 32. United Nations Publications. World Population Prospects 2019: Demographic Profiles.694 2020.

It is made available under a CC-BY 4.0 International license .

67

696 Supplementary Figures



697Reduction in R_0 (%), εReduction in R_0 (%), ε698Fig. S7: Infection attack rates for each of the six models, delineated by control and699intervention arms.

It is made available under a CC-BY 4.0 International license .





It is made available under a CC-BY 4.0 International license .





Fig. S9: The contribution of each source of bias to the total bias. Each panel shows a 707 708 different way of calculating the contribution due to that source of bias, which is calculated as the difference in efficacy of a model without that bias and a model with that bias. This can be 709 thought of as embedding the models, and subtracting adjacent pairs of models, so that the sum 710 of each pair of models is equal to the total bias. The embeddings in each panel are: A: no 711 712 bias \rightarrow mosquito movement \rightarrow human movement + mosquito movement \rightarrow full model. B: no 713 bias \rightarrow human movement \rightarrow human movement + mosquito movement \rightarrow full model. C: no

It is made available under a CC-BY 4.0 International license .

715

714 bias \rightarrow human movement \rightarrow human movement + transmission coupling \rightarrow full model.

 A_3A_3 A_2A_3 A_1A_3 A_0A_3 A_1A_3 A_2A_3 A_3A_3 A_3A_2 A_2A_2 A_1A_2 A_0A_2 A_1A_2 A_2A_2 A_3A_2 A_3A_1 A_2A_1 A_1A_1 A_0A_1 A_1A_1 A_2A_1 A_3A_1 A_3A_0 A_2A_0 A_1A_0 A_0A_0 A_1A_0 A_2A_0 A_3A_0 A_3A_1 A_2A_1 A_1A_1 A_0A_1 A_1A_1 A_2A_1 A_3A_1 A_3A_2 A_2A_2 A_1A_2 A_0A_2 A_1A_2 A_2A_2 A_3A_2 A_3A_3 A_2A_3 A_1A_3 A_0A_3 A_1A_3 A_2A_3 A_3A_3

716

717 Fig. S10: Diagram of the checkerboard arrangement. Cell coloring refers to whether or not someone is the treatment or control cluster. In this case, the central cluster is an individual's 718 home cluster. A_i describes the proportion of time someone spends in a cluster i clusters from 719 720 their home cluster in one direction. A_iA_i is then the proportion of time someone spends in a 721 cluster i clusters away in one direction, and i in the other. 722